ENTITY
CSPC Pharmaceutical Group

CSPC Pharmaceutical Group (1093 HK)

247
Analysis
Health CareChina
CSPC Pharmaceutical Group Limited, through its subsidiaries, manufactures and sells pharmaceutical products. The Company's products include vitamin C, antibiotics and common generic drugs. The Company is also engages in the development of innovative drugs and antibiotics.
more
29 Mar 2022 08:53

Hutchmed China Ltd (13.HK/HCM.US) - Big but Not Strong

Li Ka-shing's original intention for Hutchmed is not on innovative drugs. Hutchmed's current pipeline also does not have core competitiveness. So,...

Logo
294 Views
Share
24 Mar 2022 23:35

CSPC Pharmaceutical (1093 HK): 2021 Results Review- Double-Digit Top-Line Growth, Driven By Oncology

Amid pricing headwinds and continued Covid impact, CSPC’s double-digit top and bottom-line growth and pipeline progress enhance our conviction on...

Logo
406 Views
Share
09 Mar 2022 18:48

HSCEI Index Rebalance Preview (June): Great Wall Motor (2333) Should Replace Hansoh Pharma (3692)

Great Wall Motor (2333) should replace Hansoh Pharma (3692) in the HSCEI at the June rebalance. Bilibili is a close add in case Sunac is deleted....

Logo
508 Views
Share
03 Mar 2022 08:43

Suzhou Zelgen Biopharmaceuticals (688266.CH) - Uncertainty Leads to Inaccurate Prediction on Outlook

Zelgen’s key products would face fierce competition, VBP and small market size, leading to  inaccurate prediction on outlook. So we choose to be...

Logo
184 Views
Share
16 Feb 2022 09:14

Pre-IPO Biocytogen Pharmaceuticals - The Novel Development Model Offset the Pipeline's Shortcomings

We analyzed the unique development strategy of Biocytogen, and also pointed out the concerns on its pipeline. However, its business model is hard...

Logo
288 Views
Share
x